Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23193920 | 0.81 | HTR1A (0.33) | POLBLMNA | |
| SCHEMBL18464509 | 0.81 | P2RX7 (0.40) | TAAR1TUBB1SMN1; SMN2POLBGAA | |
| SCHEMBL3755393 | 0.77 | TAAR1 (0.47) | TAAR1TUBB1SMN1; SMN2POLBGAA | |
| SCHEMBL7720468 | 0.74 | TAAR1 (0.50) | TAAR1TUBB1SMN1; SMN2POLBGAA | |
| SCHEMBL19072921 | 0.74 | TAAR1 (0.45) | TAAR1TUBB1SMN1; SMN2POLBGAA | |
| SCHEMBL15490066 | 0.72 | ESR1 (0.34) | MAPT | |
| SCHEMBL13263751 | 0.70 | TAAR1 (0.45) | TAAR1TUBB1SMN1; SMN2POLBGAA | |
| SCHEMBL2908385 | 0.69 | TAAR1 (0.41) | TAAR1TUBB1SMN1; SMN2POLBGAA | |
| SCHEMBL24112122 | 0.69 | NQO2 (0.44) | TAAR1TUBB1SMN1; SMN2POLBGAA | |
| SCHEMBL19702093 | 0.69 | HTR2A (0.41) | TAAR1TUBB1SMN1; SMN2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200277342-A1 | NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-09-03 | — | — | US | disclosed |
| US-10696720-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277342-A1 | NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | TAAR1 2158/4885TUBB1 2403/4885SMN1; SMN2 4864/4885 |
| US-10696720-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | TAAR1 2471/4885TUBB1 2512/4885SMN1; SMN2 4839/4885 |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | TAAR1 2471/4885TUBB1 2512/4885SMN1; SMN2 4839/4885 |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | TAAR1 2471/4885TUBB1 2512/4885SMN1; SMN2 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.